Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Amgen's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $400.0 million for Q3 2025.

• In Q3 2025, Asset Writedowns and Impairment rose 555.74% year-over-year to $400.0 million; the TTM figure through Mar 2026 stood at $400.0 million (down 55.11% YoY), while the FY2025 annual figure was $1.2 billion, up 654.72% from the prior year.
• Asset Writedowns and Impairment for Q3 2025 stood at $400.0 million, down from $800.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $851.0 million in Q4 2023, with the low at $2.0 million in Q4 2022.
• The 4-year median for Asset Writedowns and Impairment is $64.5 million (2024), against an average of $277.1 million.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment jumped 42450.0% in 2023, then slumped 96.47% in 2024.
• Amgen's Asset Writedowns and Impairment stood at $2.0 million in 2022, then surged by 42450.0% to $851.0 million in 2023, then plunged by 96.47% to $30.0 million in 2024, then soared by 1233.33% to $400.0 million in 2025.
• Business Quant data shows AMGN's Asset Writedowns and Impairment at $400.0 million in Q3 2025, $800.0 million in Q1 2025, and $30.0 million in Q4 2024.